No Data
ScPharmaceuticals Reports Preliminary Q4 Revenue Of $12M-$12.3M; FY24 Revenue Expected To Be $36.2M-$36.5M
Express News | ScPharmaceuticals Inc - Q4 2024 Net Revenue Expected to Be $12M-$12.3M, 99% Growth Over Q4 2023
ScPharmaceuticals Inc.'s (NASDAQ:SCPH) Shift From Loss To Profit
scPharmaceuticals | 10-Q/A: Quarterly report (Amendment)
Craig-Hallum Maintains ScPharmaceuticals(SCPH.US) With Buy Rating
Craig-Hallum Issues a Buy Rating on ScPharmaceuticals (SCPH)